Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tempest Therapeutics, Inc. (TPST)

2.32   -0.59 (-20.27%) 03-31 16:00
Open: 2.97 Pre. Close: 2.91
High: 3.23 Low: 2.2801
Volume: 126,179 Market Cap: 33(M)

Technical analysis

as of: 2023-03-31 4:22:39 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.77     One year: 4.4
Support: Support1: 1.88    Support2: 1.05
Resistance: Resistance1: 3.23    Resistance2: 3.77
Pivot: 1.57
Moving Average: MA(5): 2.15     MA(20): 1.54
MA(100): 1.62     MA(250): 2.12
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 81.6     %D(3): 87.2
RSI: RSI(14): 63.3
52-week: High: 4.42  Low: 1.05
Average Vol(K): 3-Month: 24 (K)  10-Days: 61 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TPST ] has closed below upper band by 13.2%. Bollinger Bands are 262.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.23 - 3.25 3.25 - 3.26
Low: 2.25 - 2.27 2.27 - 2.28
Close: 2.3 - 2.32 2.32 - 2.34

Company Description

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Headline News

Fri, 31 Mar 2023
Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Friday? - InvestorsObserver

Wed, 29 Mar 2023
Healthcare Stocks Moving Wednesday: TPST, RNXT, ARCT, CFMS, PRQR, SHCR, PIRS, BLUE - InvestorsObserver

Wed, 29 Mar 2023
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are ... - UK

Wed, 15 Mar 2023
Tempest to Present Biomarker Data for TPST-1120 at the Society for ... - GlobeNewswire

Tue, 08 Nov 2022
Tempest Reports Third Quarter 2022 Financial Results and Provides ... - GlobeNewswire

Thu, 26 May 2022
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 11 (M)
Shares Float 8 (M)
% Held by Insiders 3.2 (%)
% Held by Institutions 71.2 (%)
Shares Short 30 (K)
Shares Short P.Month 17 (K)

Stock Financials

EPS -9.29
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.3
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -29.9
Return on Equity (ttm) -97.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.92
Qtrly Earnings Growth 0
Operating Cash Flow -33 (M)
Levered Free Cash Flow -18 (M)

Stock Valuations

PE Ratio -0.25
PEG Ratio 0
Price to Book value 0.36
Price to Sales 0
Price to Cash Flow -0.75

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2018-12-09
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.